ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Best Case Scenario for PMN

<< Previous

Bullboard Posts

Next >>

Comment by Gbathaton Jul 20, 2021 9:44pm

94 Views

Post# 33579688

RE:RE:RE:RE:Best Case Scenario for PMN

all good DKC. I figured as much and did not mean that to read as critical or anything. thanks for helping to keep the chatter going and dd flowing around here. I've been slacking on my dd lately and need to catch up. Good luck to you.

<< Previous

Bullboard Posts

Next >>

Top 10 pharmaceutical AI stocks